CFTR and cystic fibrosis: In conclusion, the assessment of the key direct pathophysiologic determinants of glucose regulation in CF patients undergoing CFTR modulators demonstrated that these treatments ameliorated neither glucose-stimulated insulin bioavailability nor insulin sensitivity and, hence, did not improve glucose tolerance.